Novacyt SA - biotechnology group focused on clinical diagnostics - Continues to expand Covid-19 portfolio. Reports expansion of PathFlow lateral flow test portfolio with Covid-19 tests, genesig Covid-19 polymerase chain reaction portfolio, PROmate Covid-19 PCR portfolio for workflow efficiency in a near-to-patient setting and SNPsig Covid-19 PCR genotyping portfolio to detect SARS-CoV-2 variants.
"The continued development and expansion of our Covid-19 portfolio demonstrates Novacyt's ability to match the rapid evolution of SARS-CoV-2 with real-time bioinformatics surveillance and accelerated product development," says Chief Executive Graham Mullis.
Adds that Primerdesign and Microgen Bioproducts, Novacyt's wholly owned subsidiaries, have been included in the National Microbiology Framework for Diagnostic Goods and Services published by PHE for a full range of clinical products, including tests within the company's accredited portfolio.
"The successful inclusion of Primerdesign and Microgen Bioproducts in the PHE National Framework Agreement, coupled with the company's investment in its commercial infrastructure to deliver new products and establish a direct sales force, means Novacyt is well positioned to develop a long-term commercial position in the UK market," it says.
Current stock price: 443.10 pence, up 20% on Friday
Year-to-date change: down 49%
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.